Trial Population:

1. Younger than 35, but at least 18 years of age

2. Hormone receptor-negative tumor (ER- and PgR-negative) and 35 to 75 years of age.

3. Hormone receptor-positive tumor, 35 to 59 years of age and presenting at least one of
the following characteristics: spread to lymph nodes, tumor > 2 cm, degree of
malignancy II-III or HER2-positive.

Inclusion Criteria:

1. Signed informed consent

2. Histologically confirmed invasive breast carcinoma which has been micro-radical
removed by breast preserving surgery or mastectomy according to DBCG's guideline

3. TOP2A normal tumor (score of 0.8 - 2.0)

Exclusion Criteria:

1. Pregnancy or breast-feeding

2. Earlier medical cancer treatment, including docetaxel, epirubicin or
cyclophosphamide.

3. Distant metastases or bilateral breast cancer (excluded after checking by means of
chest radiography, bilateral mammography and normal blood samples as a minimum).

4. Other active, malign disease in the latest 5 years, except for adequately treated and
cured carcinoma in situ cervices uteri or non-melanoma skin cancer.

5. Comorbidity score > 3 (patients with a score of 1-2 start at dose level -1).

6. Treatment with a non-approved product or test product in the latest 30 days.

7. Known severe hypersensitivity to docetaxel, epirubicin or cyclophosphamide or
auxiliary agents in these products.